Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 364

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 364
---
 consideration received € 59,835
1.2. Analysis of assets and liabilities over which control was lost
January 31, 2024
────────────────────────────────────────────────────────────────────
(Euro,
Property, plant and equipment € 4,186
Deferred tax assets 292
Other non-current assets 613
Inventories 505
Trade and other receivables 18,439
Cash and cash equivalents 19,523
Other current assets 1,161
Total assets 44,719
Other reserves ( 74)
Retirement benefit liabilities 1,003
Non-current lease liabilities 2,328
Other non-current liabilities 90
Current lease liabilities 1,308
Trade and other liabilities 28,927
Current tax payable 1,170
Current deferred income 430
Total liabilities 35,182
Net assets disposed of € 9,537

F-31

Table of Contents

1.3. Gain on disposal of the Jyseleca® business (included in other operating income in the income statement)
Year ended December 31, 2024
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
(Euro,
Upfront payment received € 50,000
Settlement for net cash and working capital 9,835
Additional adjustment working capital to be settled ( 750)
Net assets disposed of ( 9,537)
Effect of cumulative translation adjustments reclassified from equity on loss of control ( 4,095)
Fair value of the future earn-outs payable by Alfasigma to us 47,035
Contribution for R& D costs payable by us to Alfasigma ( 40,000)
Gain on disposal of subsidiaries € 52,488
The fair value of the future earn-outs at December 31, 2024 is presented on the lines “ Non-current contingent consideration receivable” and “ Trade and other receivables” in our statement of financial position.
1.4. Net cash outflow on disposal of the Jyseleca® business
Upfront payment received 50,000
Settlement for net cash and working capital 9,835
Transfer to escrow account ( 40,000)
Contribution for R& D costs paid by us to Alfasigma ( 15,000)
Earn-outs paid by Alfasigma 2,053
Less: cash and cash equivalents balances disposed of ( 19,